Janssen Pharmaceuticals, Inc.

Janssen Vaccines & Prevention B.v.

Wouter Frank Tonnis

Janik Adriaansen

Francesco Doro

Olga Labovitiadi

Ahmad Shakeb Sediq

Martinus Anne Hobbe Capelle

Compositions and methods for inducing an immune response against extra-intestinal pathogenic(ExPEC) are described. In particular, multivalent vaccines containing O-antigen polysaccharide covalently bound to an exotoxin A of(EPA) carrier protein that can withstand multiple environmental stresses are describe.

ExPEC glycoconjugate vaccine formulations

Described are compositions comprising enveloped viruses that are not MVA, a sulfate salt at a concentration of about 5 mM to about 300 mM and a buffer, and the composition has a pH of about 6.0 to about 8.5. It also discloses methods for stabilizing an enveloped virus composition by preparing said viral formulation.

Stable virus-containing composition

Described herein are compositions and pharmaceutical compositions including poxviruses, in particular vaccinia virus such as modified vaccinia Ankara (MVA) virus, a sulfate salt at a concentration between about 5 mM and 300 mM and a buffer, wherein the composition has a pH of between about 6.0 and 8.5. Also described are methods for stabilizing a poxvirus composition by preparing said viral formulation.

Compositions and methods for inducing an immune response against extra-intestinal pathogenic(ExPEC) are described. In particular, multivalent vaccines containing O-antigen polysaccharide covalently bound to an exotoxin A of(EPA) carrier protein that can withstand multiple environmental stresses are described.

Compositions and methods for inducing an immune response against extra-intestinal pathogenic(ExPEC) are described. In particular, multivalent vaccines containingantigen polysaccharide covalently bound to a exotoxin A of(EPA) carrier protein that can withstand multiple environmental stresses are described.

Growing community of inventors

Berlin, Germany

Wouter Frank Tonnis